Trial Watch

Abstract

Immunostimulatory monoclonal antibodies (mAbs) exert antineoplastic effects by eliciting a novel or reinstating a pre-existing antitumor immune response. Most often, immunostimulatory mAbs activate T lymphocytes or natural killer (NK) cells by inhibiting immunosuppressive receptors, such as cytotoxic T lymphocyte-associated protein 4 (CTLA4) or programmed cell death 1 (PDCD1, best known as PD-1), or by engaging co-stimulatory receptors, like CD40, tumor necrosis factor receptor superfamily, member 4 (TNFRSF4, best known as OX40) or TNFRSF18 (best known as GITR). The CTLA4-targeting mAb ipilimumab has been approved by the US Food and Drug Administration for use in patients with unresectable or metastatic melanoma in 2011. The therapeutic profile of ipilimumab other CTLA4-blocking mAbs, such as tremelimumab, is currently being assessed in subjects affected by a large panel of solid neoplasms. In the last few years, promising clinical results have also been obtained with nivolumab, a PD-1-targeting mAb formerly known as BMS-936558. Accordingly, the safety and efficacy of nivolumab and other PD-1-blocking molecules are being actively investigated. Finally, various clinical trials are underway to test the therapeutic potential of OX40- and GITR-activating mAbs. Here, we summarize recent findings on the therapeutic profile of immunostimulatory mAbs and discuss clinical trials that have been launched in the last 14 months to assess the therapeutic profile of these immunotherapeutic agents.

Keywords: :

• CD137
• checkpoint blockade
• immunogenic chemotherapy
• immunosuppression
• lirilumab
• IPH2101
• PD-L1

Introduction

A large panel of monoclonal antibodies (mAbs) is currently approved by the US Food and Drug Administration (FDA) and other international regulatory agencies, including the European Medicines Agency (EMA), for the treatment of conditions as diverse as autoimmune diseases and cancer.^1,2 For illustrative purposes, antineoplastic mAbs can be subdivided into 2 large groups: (1) tumor-targeting mAbs, which directly bind to malignant cells or intercept trophic signals delivered by the tumor stroma;² and (2) immunostimulatory mAbs, which operate by interacting with (hence modulating the function of) components of the immune system.^3-5

As we have discussed in previous issues of OncoImmunology,^6-8 the therapeutic potential of tumor-targeting mAbs may or may not involve immune effectors. Thus, while some of these molecules, such as the vascular endothelial growth factor (VEGF)-specific IgG1 bevacizumab,^9,10 mainly exert antineoplastic effects by inhibiting pro-survival or mitogenic signaling pathways, others, such as the CD20-targeting IgG1 rituximab,^11-13 near-to-completely rely on effector mechanisms of innate immunity, including antibody-dependent cell-mediated cytotoxicity (ADCC),^2,14-17 antibody-dependent cellular phagocytosis (ADCP),¹⁸ and complement-dependent cytotoxicity (CDC).^19,20 Of note, some tumor-targeting mAbs, such as cetuximab, a chimeric IgG1 specific for the epidermal growth factor receptor (EGFR),^21,22 appear to inhibit tumor growth via both cancer cell-autonomous and immune system-dependent mechanisms.^23-26 In addition, tumor-targeting mAbs can be harnessed as carriers for the selective delivery to malignant cells of toxins or radionuclides. This is the case of the CD20-targeting molecules ⁹⁰Y-ibritumomab tiuxetan and ¹³¹I-tositumomab, which are currently approved for the treatment of non-Hodgkin’s lymphoma (NHL).^27,28

The efficacy of immunostimulatory mAbs invariably relies on the elicitation of a novel or on the reactivation of a pre-existing immune response against malignant cells.^3-5 So far, this has been achieved through three general strategies: (1) the blockade of inhibitory receptors such as cytotoxic T lymphocyte-associated protein 4 (CTLA4)^29-31 and programmed cell death 1 (PDCD1, best known as PD-1),^32-36 both of which are expressed by activated T lymphocytes, or various members of the killer cell immunoglobulin-like receptor (KIR) family, which are found on the surface of natural killer (NK) cells;^37-40 (2) the activation of co-stimulatory receptors such as tumor necrosis factor receptor superfamily, member 4 (TNFRSF4, best known as OX40)^41-44 and TNFRSF18 (best known as GITR),^45,46 which are expressed by activated CD4⁺ and CD8⁺ T cells; (3) the neutralization of soluble immunosuppressive factors, such as transforming growth factor β1 (TGFβ1) (Table 1).^47-51

Table 1. Immunostimulatory mAbs currently in clinical development

Target(s)	mAb	Aliases	Isotype	Source	Activity	Owner
CD27	CDX-1127	1F5	n.a.	Human	Agonist	Celldex
CD40	Chi Lob 7/4	-	IgG1	Chimeric	Agonist	Cancer Research UK
	CP-870,893	-	IgG2	Human	Agonist	Pfizer
	Dacetuzumab	SGN-40 huS2C6	IgG1	Humanized	Agonist	Seattle Genetics
	Lucatumumab	HCD122	IgG1	Human	Agonist	Novartis Pharmaceuticals
CD274 (PD-L1, B7-H1)	BMS-936559	MDX-1105	IgG4	Human	Antagonist	Bristol–Myers Squibb
	MEDI4736	-	IgG1	Human	Antagonist	Medimmune
	MPDL3280A	RG7446	IgG1	Human	Antagonist	Genentech (Roche)
	MSB0010718C	-	n.a.	Human	Antagonist	Serono (Merck)
CTLA4	Ipilimumab	BMS-734016 MDX-010 MDX-101 Yervoy^®	IgG1κ	Human	Antagonist	Bristol–Myers Squibb
	Tremelimumab	CP-675,206 Ticilimumab	IgG2	Human	Antagonist	Pfizer
KIR	IPH2101	1–7F9	IgG4	Human	Antagonist	Innate Pharma
	Lirilumab	BMS-986015 IPH2102	IgG4	Human	Antagonist	Bristol–Myers Squibb
PDCD1 (PD-1)	AMP-224	-	IgG1 chimera	Human	Antagonist	Amplimmune (Medimmune, AstraZeneca)
	Lambrolizumab	MK-3475	IgG4	Humanized	Antagonist	Merck
	Nivolumab	BMS-936558 MDX1106 ONO-4538	IgG4	Human	Antagonist	Bristol–Myers Squibb
	Pidilizumab	CT-011	IgG1κ	Humanized	Antagonist	CureTech
MHCII	IMP321	-	IgG1 chimera	Human	Agonist	Immutep
PDCD1LG2 (PD-L2, B7-DC)	rHIgM12B7	-	IgM	Human	Agonist	Mayo Foundation
TGFβ1	Fresolimumab	GC1008	IgG4κ	Human	Antagonist	Sanofi–Aventis
TNFRSF4 (OX40)	9B12	-	IgG1	Murine	Agonist	AgonOx
	MEDI6469	-	n.a.	Murine	Agonist	Medimmune (AstraZeneca)
TNFRSF9 (CD137, 4–1BB)	Urelumab	BMS-663513	IgG4	Human	Agonist	Bristol-Myers Squibb
	PF-05082566	-	IgG2	Human	Agonist	Pfizer
TNFRSF18 (GITR)	TRX518	-	IgG1	Humanized	Agonist	Tolerex

Abbreviations: CTLA4, cytotoxic T lymphocyte-associated protein 4; KIR, killer cell immunoglobulin-like receptor; mAb, monoclonal antibody; MHCII, MHC Class II; n.a., not available; PDCD1, programmed cell death 1; PDCD1LG2, PDCD1 ligand 2; TGFβ1, transforming growth factor β1; TNFRSF, tumor necrosis factor receptor superfamily.

At odds with their tumor-targeting counterparts, which have attracted attention as potential anticancer agents as early as in the 1980s,^52-55 immunostimulatory mAbs have been the focus of intensive preclinical and clinical investigation only with the advent of the 21st century. At least in part, this relates to the fact that tumors have long been considered as immunologically silent entities, a notion that begun to change only in the late 1990s, thanks to the theoretical foundations provided by Polly Matzinger’s “danger theory.”^56,57 In spite of such a delayed kickoff, however, the clinical development of immunostimulatory antibodies has proceeded at a rapid pace, culminating in 2011 with the approval of ipilimumab, a fully human CTLA4-targeting IgG1κ also known as MDX-010, MDX-101, and BMS-734016 (now commercialized by Bristol–Myers Squibb under the trade mark Yervoy^®), for use in patients with unresectable or metastatic melanoma.^58-60 Ipilimumab nowadays represents the sole immunostimulatory mAb licensed by regulatory agencies for use in cancer patients, whereas no less than 14 tumor-targeting mAbs are currently employed in the clinic as part of FDA-approved immunotherapeutic regimens.^1,2,8 This said, starting with the late 2000s, promising results have also been obtained in clinical trials investigating the safety and therapeutic profile of other immunostimulatory mAbs, including (1) the PD-1-targeting molecules nivolumab, a human IgG4 also known as BMS-936558, MDX-1106, and ONO-4538,^61-64 and lambrolizumab, a humanized IgG4 also known as MK-3475;⁶⁵ (2) BMS-936559 (also known as MDX-1105), a human IgG4 that targets the PD-1 ligand CD274 (best known as PD-L1);⁶⁶ and (3) the CD40 agonist mAbs CP-870,893 (a human IgG2),⁶⁷ and dacetuzumab, a humanized IgG1 also known as SGN-40 and huS2C6.^68,69

Fully reflecting their immunostimulatory nature, mAbs may provoke immune reactions against self antigens that, at least potentially, may result in a life-threatening functional and/or structural damage to healthy tissues.^3,4 However, these reactions most often fail to reach a clinically meaningful amplitude and can be controlled with corticosteroids or other immunosuppressants.^3,4 Thus, immunostimulatory mAbs stand out as a relatively safe and well tolerated immunotherapeutic regimen, most frequently causing mild and controllable adverse effects including (but not limited to) skin rashes, pruritus, fatigue, nausea, and diarrhea.^3,4 As a standalone exception, urelumab (also known as BMS-663513), which operates as an agonist of the co-stimulatory receptor TNFRSF9 (best known as CD137 or 4–1BB), has been associated with severe hepatotoxicity (in particular when employed at high doses).^70,71

We have summarized recent advances on the clinical use of tumor-targeting mAbs in the latest issue of OncoImmunology.⁸ Here, along the lines of our monthly Trial Watch series,^72-75 we will restrict our focus on immunostimulatory antibodies, discussing the results of clinical trials published in the last 14 mo and commenting on studies launched in the same period to evaluate the safety and efficacy of this immunotherapeutic paradigm in cancer patients.

Update on Clinical Reports

During the last 14 mo, the results of no less than 19 clinical trials investigating the therapeutic potential of immunostimulatory mAbs in cancer patients have been published in peer-reviewed scientific journals (source http://www.ncbi.nlm.nih.gov/pubmed). More than half of these studies involved mAbs that antagonize the delivery of inhibitory signals to immune effector cells, including the CTLA4-targeting agents ipilimumab^76-82 and tremelimumab (a human IgG2 also known as ticilimumab or CP-675,206),^83-85 the PD-1-specific mAbs nivolumab and lambrolizumab,^82,86,87 as well as IPH2101 (a KIR-inhibitory human IgG4 also known as 1-7F9).^88,89 In addition, 6 studies involved mAbs that directly operate as agonists for co-stimulatory receptors, including the CD40-targeting molecules dacetuzumab, CP-870,893 and lucatumumab (a human IgG1 also known as HCD122),^90-93 9B12, a murine IgG1 that triggers OX40 signaling,⁹⁴ as well as IMP321, an IgG- and lymphocyte-activation gene 3 (LAG3)-based chimera that binds to, hence activating, MHC Class II molecules (Table 2).⁹⁵

Table 2. Recently published clinical trials investigating the therapeutic profile of immunostimulatory mAbs.*

Target	mAb	Indication(s)	Phase	Note	Ref.
CD40	CP-870,893	Pancreatic cancer	I	In combination with gemcitabine	92
		Advanced solid tumors	I	In combination with paclitaxel and carboplatin	90
	Dacetuzumab	DLBCL	Pilot	In combination with rituximab and gemcitabine	91
	Lucatumumab	CLL	I	As single agent	93
		MM	I	As single agent	108
CTLA4	Ipilimumab	Melanoma	I	In combination with vemurafenib	78
			I	Combined with nivolumab	82
			III	As single agent or combined with dacarbazine	76
		Pancreatic cancer	Ib	As single agent or combined with a GM-CSF-secreting vaccine	80
		Prostate carcinoma	I/II	In combination with a GM-CSF-secreting allogeneic vaccine	77
			I/II	Combined with GM-CSF	81
		SCLC	II	In combination with paclitaxel and carboplatin	79
	Tremelimumab	Melanoma	I	As single agent	83
			I	In combination with the TLR9 agonist PF-3512676	85
			III	As single agent	84
KIR	IPH2101	AML	I	As single agent	88
		MM	I	As single agent	89
MHCII	IMP321	Pancreatic carcinoma	I	In combination with gemcitabine	95
PDCD1 (PD-1, CD279)	Lambrolizumab	Melanoma	I	As single agent	87
	Nivolumab	Melanoma	I	Combined with ipilimumab	82
		Advanced solid tumors	I	As single agent	86
TNFRSF4 (OX40)	9B12	Advanced solid tumors	I	As single agent	94

Abbreviations: AML, acute myeloid leukemia; CLL, chronic lymphocytic leukemia; CTLA4, cytotoxic T lymphocyte-associated protein 4; DLBCL, diffuse large B-cell lymphoma; GM-CSF, granulocyte macrophage colony-stimulating factor; KIR, killer cell immunoglobulin-like receptor; mAb, monoclonal antibody; MHCII, MHC Class II; MM, multiple myeloma; PDCD1, programmed cell death 1; SCLC, small cell lung carcinoma; TLR9, Toll-like receptor 9; TNFRSF, tumor necrosis factor receptor superfamily. *between 2012, October 1st and the day of submission.

Ipilimumab has recently been tested (1) together with the BRAF inhibitor vemurafenib in patients with metastatic melanoma bearing a BRAF V600 mutation;⁷⁸ (2) combined with paclitaxel (a microtubular inhibitor and hyperploidizing agent of the taxane family)^96,97 and carboplatin (a second-generation platinum derivative)^98,99 as first-line therapy in subjects bearing extensive small-cell lung cancer lesions;⁷⁹ (3) alone or in combination with a granulocyte macrophage colony-stimulating factor (GM-CSF)-secreting allogeneic vaccine^100,101 in pancreatic ductal adenocarcinoma patients;⁸⁰ and (4) as part of a nivolumab-based immunotherapeutic regimen in patients with advanced melanoma.⁸² In addition, (1) Sherrill and colleagues evaluated the quality-adjusted survival of patients enrolled in study CA184024, a multinational, randomized, double-blind, Phase III trial testing dacarbazine (an alkylating agent currently approved by the US FDA for the treatment of Hodgkin’s lymphoma and melanoma) alone vs. dacarbazine plus ipilimumab in subjects with previously untreated metastatic melanoma;^59,76 (2) Santegoets and collaborators performed an exploratory T-cell monitoring study in the context of Phase I/II dose escalation/expansion trial testing ipilimumab plus a GM-CSF-secreting allogeneic vaccine in prostate carcinoma patients;⁷⁷ and (3) Kwek and co-authors monitored the humoral immune responses elicited by the co-administration of ipilimumab and a fixed dose of GM-CSF^102,103 in subjects with prostate cancer.⁸¹ In these clinical settings, ipilimumab-based immune(chemo)therapy was well tolerated and associated with promising clinical responses,^79,80,82 with a single exception.⁷⁸ Indeed, in 2 distinct cohorts of melanoma patients, the co-administration of ipilimumab and vemurafenib at full approved doses was associated with grade 3 elevations in circulating alanine aminotransferase (ALT) and aspartate aminotransferase (AST).⁷⁸ Although such hepatotoxic effects were asymptomatic and reversible upon the temporary discontinuation of treatment or the administration of glucocorticoids, this Phase I clinical trial was promptly closed to further patient accrual.⁷⁸

The clinical potential of tremelimumab, employed as a standalone therapeutic intervention or combined with the Toll-like receptor 9 (TLR9) agonist PF-3512676,^104-106 has recently been assessed in patients affected by metastatic melanoma^83-85 or other advanced neoplasms.⁸⁵ In the context of a Phase I clinical trial, the combination of tremelimumab with PF-3512676 was well tolerated, but evoked measurable clinical responses in 2 out of 21 patients only.⁸⁵ Along similar lines, in the context of a large, randomized, Phase III study, no statistically significant survival advantage could be documented in metastatic melanoma patients receiving tremelimumab vs. standard-of-care chemotherapy, although response duration (measured from the time of randomization) was significantly longer in the tremelimumab arm.⁸⁴ Based on such a lack of efficacy, the A3671009 study (NCT00257205) has been discontinued.¹⁰⁷

The safety and efficacy of PD-1-targeting mAbs have recently been investigated in 2 distinct cohorts of melanoma patients, receiving either lambrolizumab as a single agent in the context of a Phase I clinical trial (NCT01295827),⁸⁷ or nivolumab coupled to ipilimumab, again as part of a Phase I study (NCT01024231).⁸² In addition, the long-term therapeutic potential of nivolumab given as a standalone intervention has been assessed in a mixed patient cohort, encompassing melanoma, renal cell carcinoma as well as colorectal carcinoma patients.⁸⁶ In these settings, the administration of PD-1-targeting mAbs alone was associated with relatively mild (grade 1 or 2) side effects.^86,87 Conversely, the co-administration of nivolumab and ipilimumab provoked grade 3 or 4 adverse reactions in a consistent proportion of melanoma patients.⁸² Still, (1) such side effects were qualitatively similar to those previously associated with either nivolumab or ipilimumab monotherapy and were generally reversible; and (2) the combined inhibition of CTLA4- and PD-1-dependent immunosuppression was associated with an objective response in 53% of patients, invariably manifesting with a reduction in tumor burden of 80% or more.⁸²

The clinical potential of mAbs directly targeting NK cells, rather than T lymphocytes, has recently been assessed in patients affected by acute myeloid leukemia (EUDRACT 2005–005298–31)⁸⁸ or relapsed/refractory multiple myeloma (NCT00552396).⁸⁹ In both these Phase I sequential-cohort dose-escalation studies, IPH2101 was administered as a single agent, provoking limited side effects at doses that fully inhibit KIRs.^88,89

Finally, the safety and efficacy of immunostimulatory mAbs that operate as agonists for co-stimulatory receptors have recently been investigated (invariably in Phase I settings) (1) in patients with chronic lymphocytic leukemia (CLL) or relapsed/refractory multiple myeloma, receiving lucatumumab as a single agent in the context of sequential-cohort dose-escalation studies;^93,108 (2) in subjects affected by advanced pancreatic ductal adenocarcinoma, who were treated with CP-870,893 plus gemcitabine-based chemotherapy;⁹² (3) in individuals bearing advanced solid tumors, receiving CP-870,893 coupled to carboplatin and paclitaxel;⁹⁰ (4) in patients with relapsed/refractory diffuse large B-cell lymphoma, who were given dacetuzumab in combination with rituximab and gemcitabine;⁹¹ (5) in individuals bearing advanced neoplasms, receiving 9B12 in combination with various adjuvants (NCT01644968);⁹⁴ and (6) in patients with advanced pancreatic adenocarcinoma, receiving IMP321 plus gemcitabine-based chemotherapy.⁹⁵ Globally, these immunostimulatory mAbs were well tolerated but exerted limited clinical efficacy.^90-95,108

In summary, the results of the clinical studies reported above suggest that immunostimulatory mAbs are well tolerated by cancer patients, especially when administered as standalone interventions, yet elicit limited clinical responses in these conditions. Conversely, combinatorial approaches such as the co-administration of nivolumab and ipilimumab are associated not only with an increased incidence and severity of adverse effects, but also with improved clinical activity.⁸²

Update on Clinical Trials Testing Immunostimulatory Monoclonal Antibodies

When this Trial Watch was being redacted (November 2013), official sources listed 60 clinical trials launched after 2012, October 1st to evaluate the therapeutic profile of immunostimulatory mAbs in cancer patients (source http://www.clinicaltrials.gov).

For obvious advantages related to its approval status, more than half (36) of these studies aim at investigating the clinical profile of ipilimumab, either as a standalone intervention or combined with radiotherapy, conventional chemotherapeutics, targeted anticancer drugs or other immunostimulatory agents. In particular, ipilimumab is being tested as part of immunochemotherapeutic or immunoradiotherapeutic regimens in melanoma patients (NCT01701674; NCT01703507; NCT01708941; NCT01709162; NCT01715077; NCT01730157; NCT01740297; NCT01740401; NCT01767454; NCT01769222; NCT01783938; NCT01789827; NCT01810016; NCT01827111; NCT01838200; NCT01844505; NCT01856023; NCT01866319; NCT01879306), the sole oncological indication for which this CTLA4-targeting mAb is licensed by regulatory agencies, as well as in cohorts of individuals affected by various hematological malignancies (NCT01729806; NCT01757639; NCT01769222; NCT01822509; NCT01896999; NCT01919619), prostate carcinoma (NCT01804465; NCT01832870), head and neck cancer (NCT01860430; NCT01935921), non-small cell lung carcinoma (NSCLC) (NCT01820754), cervical carcinoma (NCT01711515), Merkel cell carcinoma (NCT01913691), pancreatic cancer (NCT01896869), colorectal carcinoma (NCT01769222), and various advanced/metastatic solid tumors (NCT01738139; NCT01750580; NCT01750983; NCT01928394). Alongside, the safety and efficacy of the other CTLA4-targeting mAb tremelimumab are being assessed in cohorts of malignant mesothelioma patients, receiving tremelimumab as a single agent (NCT01843374), liver cancer patients, who are treated with a combination of tremelimumab and trans-arterial catheter chemoembolization or radiofrequency ablation (NCT01853618), and subjects affected by various solid neoplasms, who are given tremelimumab plus MEDI4736 (a human IgG1 specific for PD-L1) (NCT01975831). Of note, MEDI4736 as well as two other PD-L1 targeting mAbs, namely MPDL3280A (a human IgG1 also known as RG7446) and MSB0010718C, are being investigated also as standalone therapeutic interventions in cohorts of patients affected by NSCLC (NCT01846416; NCT01903993) or various advanced solid neoplasms (NCT01772004; NCT01938612; NCT01943461) (Table 3).

Table 3. Clinical trials recently launched to evaluate the therapeutic profile of immunostimulatory mAbs.*

mAb	Target(s)	Indication(s)	Phase	Status	Note	Ref.
Anti-OX40	TNFRSF4 (OX40)	Breast carcinoma	I/II	Recruiting	Combined with SBRT	NCT01862900
Ipilimumab	CTLA4	AML MDS	I	Recruiting	As single agent	NCT01757639
		Cervical carcinoma	I	Recruiting	Combined with cisplatin and radiation therapy	NCT01711515
		CRC Lymphoma Melanoma	I/II	Recruiting	Combined with radiation therapy	NCT01769222
		Hematological malignancies	I	Recruiting	As single agent	NCT01822509
		HNC	I	Recruiting	Combined with cetuximab and radiation therapy	NCT01860430
			I	Recruiting	Combined with cetuximab and radiation therapy	NCT01935921
		Hodgkin's lymphoma	I	Not yet recruiting	Combined with brentuximab vedotin	NCT01896999
		Leukemia Lymphoma	n.a.	Not yet recruiting	Combined with lenalidomide	NCT01919619
		Lymphoma	I	Recruiting	Combined with rituximab	NCT01729806
		Melanoma	n.a.	Not yet recruiting	As single agent	NCT01715077
			n.a.	Not yet recruiting	In the context of ^99Tc-based imaging procedures	NCT01789827
			n.a.	Recruiting	Followed by lymphodepletion, TIL infusion and IL-2	NCT01701674
			0	Recruiting	Combined with radioembolization	NCT01730157
			I	Recruiting	Combined with SRS or WBRT	NCT01703507
			I	Recruiting	Combined with dabrafenib ± trametinib	NCT01767454
			I	Recruiting	Combined with NY-ESO-1-targeting vaccine ± montanide	NCT01810016
			I	Recruiting	Combined with BCG	NCT01838200
			I/II	Recruiting	As single agent or combined with oncolytic virotherapy	NCT01740297
			II	Active not recruiting	Combined with cyclophosphamide	NCT01740401
			II	Not yet recruiting	As single agent	NCT01879306
			II	Recruiting	As single agent or combined with IFNα-2b	NCT01708941
			II	Recruiting	As single agent	NCT01709162
			II	Recruiting	Combined with nivolumab	NCT01783938
			II	Recruiting	Combined with paclitaxel	NCT01827111
			III	Recruiting	Combined with nivolumab	NCT01844505
			III	Recruiting	Combined with lambrolizumab	NCT01866319
			IV	Recruiting	Combined with high-dose IL-2	NCT01856023
		Merkel cell carcinoma	II	Not yet recruiting	As single agent	NCT01913691
		NSCLC	I	Recruiting	Combined with carboplatin, cisplatin and paclitaxel	NCT01820754
		Pancreatic cancer	II	Not yet recruiting	As single agent or combined with a GM-CSF-secreting vaccine	NCT01896869
		Prostate cancer	I	Recruiting	Combined with sipuleucel-T	NCT01832870
			II	Active not recruiting	After sipuleucel-T treatment	NCT01804465
		Advanced solid tumors	I	Recruiting	Combined with imatinib	NCT01738139
			I	Recruiting	Combined with lirilumab	NCT01750580
			I	Recruiting	Combined with lenalidomide	NCT01750983
			I/II	Not yet recruiting	Combined with nivolumab	NCT01928394
Lambrolizumab	PDCD1 (PD-1, CD279)	CRC	II	Recruiting	As single agent	NCT01876511
		Hematological malignancies	I	Not yet recruiting	As single agent	NCT01953692
		Melanoma	II	Active not recruiting	As single agent	NCT01704287
			III	Recruiting	Combined with ipilimumab	NCT01866319
		NSCLC	II/III	Recruiting	As single agent	NCT01905657
		Advanced solid tumors	I	Recruiting	As single agent or combined with conventional chemotherapy	NCT01840579
			I	Recruiting	As single agent	NCT01848834
Lirilumab	KIR	Advanced solid tumors	I	Recruiting	Combined with nivolumab	NCT01714739
			I	Recruiting	Combined with ipilimumab	NCT01750580
MEDI4736	CD274 (PD-L1, B7-H1)	Advanced solid tumors	I	Not yet recruiting	Combined with tremelimumab	NCT01975831
			I	Recruiting	As single agent	NCT01938612
MPDL3280A	CD274 (PD-L1, B7-H1)	NSCLC	II	Recruiting	As single agent	NCT01846416
			II	Recruiting	As single agent	NCT01903993
MSB0010718C	CD274 (PD-L1, B7-H1)	Advanced solid tumors	I	Recruiting	As single agent	NCT01772004
			I	Recruiting	As single agent	NCT01943461
Nivolumab	PDCD1 (PD-1, CD279)	Melanoma	II	Recruiting	Combined with ipilimumab	NCT01783938
			II	Recruiting	Combined with ipilimumab	NCT01927419
			III	Recruiting	As single agent	NCT01721746
			III	Recruiting	As single agent	NCT01721772
			III	Recruiting	Combined with ipilimumab	NCT01844505
		NSCLC	II	Active not recruiting	As single agent	NCT01721759
			II	Recruiting	Combined with azacitidine ± entinostat	NCT01928576
		Advanced solid tumors	I	Recruiting	Combined with lirilumab	NCT01714739
			I	Recruiting	As single agent or combined with immunotherapy	NCT01968109
			I/II	Not yet recruiting	As single agent or combined with ipilimumab	NCT01928394
Pidilizumab	PDCD1 (PD-1, CD279)	Glioma	I/II	Not yet recruiting	As single agent	NCT01952769
Tremelimumab	CTLA4	HCC	I	Recruiting	Combined with RFA and TACE	NCT01853618
		Mesothelioma	II	Recruiting	As single agent	NCT01843374
		Advanced solid tumors	I	Not yet recruiting	Combined with MEDI4736	NCT01975831
Urelumab	TNFRSF9 (CD137, 4–1BB)	CLL NHL	I	Recruiting	Combined with rituximab	NCT01775631

Abbreviations: AML, acute myeloid leukemia; BCG, bacillus Calmette-Guérin; CLL, chronic lymphocytic leukemia; CRC, colorectal carcinoma; CTLA4, cytotoxic T lymphocyte-associated protein 4; GM-CSF, granulocyte macrophage colony-stimulating factor; HCC, hepatocellular carcinoma; HNC, head and neck cancer; IFNα-2b, interferon α-2b; IL, interleukin; KIR, killer cell immunoglobulin-like receptor; mAb, monoclonal antibody; MDS, myelodysplastic syndrome; n.a., not available; NHL, Non-Hodgkin's lymphoma; NSCLC, non-small cell lung carcinoma; PDCD1, programmed cell death 1; RFA, radiofrequency ablation; SBRT, stereotactic body radiation therapy; SRS, stereotactic radiosurgery; TACE, transarterial catheter chemoembolization; TIL, tumor-infiltrating lymphocyte; TNFRSF, tumor necrosis factor receptor superfamily; WBRT; whole-brain radiation therapy. *between 2012, October 1st and the day of submission.

As a matter of fact, targeting PD-1-dependent immunosuppression currently stands out as the experimental mAb-based immunotherapeutic paradigm most intensively investigated in clinical settings. Thus, nivolumab is being tested, most often as a standalone intervention or combined with ipilimumab, in patients with melanoma (NCT01721746; NCT01721772; NCT01783938; NCT01844505; NCT01927419), NLSLC (NCT01721759; NCT01928576), glioma (NCT01952769) or other solid neoplasms (NCT01714739; NCT01928394; NCT01968109). Alongside, the safety and therapeutic profile of lambrolizumab, most frequently employed as a single agent or together with ipilimumab, are being assessed in cohorts of subjects bearing melanoma (NCT01704287; NCT01866319), NSCLC (NCT01840579; NCT01905657), hematological malignancies (NCT01953692), colorectal carcinoma with high degrees of microsatellite instability (NCT01876511), or advanced/metastatic tumors (NCT01840579; NCT01848834) (Table 3).

Finally, some interest is growing around the possibility to harness the antineoplastic activity of NK cell-targeting mAbs as well as mAbs that operate as agonists for co-stimulatory T-cell and NK-cell receptors. In this setting, lirilumab (a human IgG4 that antagonizes KIRs, also known as IPH2102)¹⁰⁹ is being tested in combination with ipilimumab or nivolumab for the treatment of patients bearing advanced solid malignancies (NCT01714739; NCT01750580). Moreover, the safety and therapeutic potential of the TNFRSF9-activating mAb urelumab¹¹⁰ and a not better specified OX40-activating mAb, combined with rituximab and stereotactic body radiation, respectively,^6,7,111 are being assessed in cohorts of patients with CLL, NHL (NCT01775631) or metastatic breast carcinoma (NCT01862900) (Table 3).

As for the clinical trials listed in our previous Trial Watches dealing with this topic,^6,7 only NCT01034787 has changed status. As a matter of fact, the status of NCT01034787, a Phase 2 trial testing intravenous tremelimumab in patients affected by uveal melanoma, is no longer available because the information relative to this study has not been verified recently (source http://www.clinicaltrials.gov).

Concluding Remarks

Similar to their tumor-targeting counterparts,⁸ immunostimulatory mAbs are being intensively investigated for their ability to mediate therapeutically relevant antineoplastic effects. However, while tumor-targeting mAbs are designed to specifically bind to malignant, stromal or endothelial components of neoplastic lesions or to neutralize trophic signals delivered by the tumor stroma,^1,2 most immunostimulatory mAbs modulate general mechanisms that control innate and adaptive immune responses, de facto operating in a relatively unspecific manner.^3,4

Based on this consideration, one would expect immunostimulatory mAbs to provoke more severe side effects than their tumor-targeting counterparts^3,4 and to display a therapeutic activity resembling that of other relatively unspecific immunostimulatory interventions, such as TLR agonists,^{104,105,112,113} specific cytokines,^102,103 and immunogenic chemotherapeutics.^{74,75,114-116} Accumulating clinical evidence actually suggests that immunostimulatory mAbs are generally well tolerated by cancer patients, in particular when administered as standalone therapeutic interventions.^3,4 Conversely, the true clinical potential of most immunostimulatory mAbs employed as single agents remains matter of debate. So far, ipilimumab (the sole immunostimulatory mAb currently approved for use in humans) has been shown to exert robust therapeutic effects only in patients affected by melanoma,^58-60 a type of tumor that (1) is considered as inherently immunogenic, and (2) at least in part, responds to other unspecific immunostimulants, including high-dose interleukin-2 and interferon α2b.^102,103 Moreover, the clinical efficacy of ipilimumab seems a unique prerogative of this mAb rather than a general feature of CTL4-targeting mAbs such as tremelimumab.⁸⁴ The development of immunostimulatory mAbs is in its infancy and further studies are required to obtain profound insights into the pharmacodynamics and pharmacokinetic properties of molecules that are conceived to target the same immunomodulatory receptor yet exhibit differential clinical activity. As it stands, immunomodulatory mAbs hold great promise as tools to potentiate tumor-targeting immune responses elicited by active immunotherapeutic interventions, including recombinant vaccines,^117,118 dendritic cell-based approaches,^{100,101,119,120} and adoptive T-cell transfer.^121-124 The future will tell whether immunostimulatory mAbs other than ipilimumab will add to the growing list of FDA-approved anticancer immunotherapeutics.

Abbreviations:
CLL	=	chronic lymphocytic leukemia
CTLA4	=	cytotoxic T lymphocyte-associated protein 4
FDA	=	Food and Drug Administration
GM-CSF	=	granulocyte macrophage colony-stimulating factor
KIR	=	killer cell immunoglobulin-like receptor
mAb	=	monoclonal antibody
NHL	=	non-Hodgkin’s lymphoma
NK	=	natural killer
NSCLC	=	non-small cell lung carcinoma
TNFRSF	=	tumor necrosis factor receptor superfamily, member
TLR	=	Toll-like receptor

Disclosure of Potential Conflicts of Interest

No potential conflicts of interest were disclosed.

Acknowledgments

Authors are supported by the Ligue contre le Cancer (équipe labelisée); Agence National de la Recherche (ANR); Association pour la recherche sur le cancer (ARC); Cancéropôle Ile-de-France; AXA Chair for Longevity Research; Institut National du Cancer (INCa); Fondation Bettencourt–Schueller; Fondation de France; Fondation pour la Recherche Médicale (FRM); the European Commission (ArtForce); the European Research Council (ERC); the LabEx Immuno-Oncology; the SIRIC Stratified Oncology Cell DNA Repair and Tumor Immune Elimination (SOCRATE); the SIRIC Cancer Research and Personalized Medicine (CARPEM); and the Paris Alliance of Cancer Research Institutes (PACRI).

Citation: Aranda F, Eggermont A, Vacchelli E, Galon J, Chernyavsky A, Zitvogel L, Kroemer G, Galluzzi L. Trial Watch - Immunostimulatory monoclonal antibodies in cancer therapy. OncoImmunology 2014; 3:e27297; 10.4161/onci.27297